PART I Overview We are a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and other indications. Our POZ drug delivery technology is designed to enable certain existing drugs and novel drug candidates to be modified in a way that provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADC...
Q2 FY2026 — expected 2026-09-18
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-25 | 2025-12-31 | 0001708599-26-000016 | EDGAR | 81K words |
| 2025-03-24 | 2024-12-31 | 0001708599-25-000027 | EDGAR | — |
| 2024-03-22 | 2023-12-31 | 0001493152-24-011022 | EDGAR | — |
| 2023-03-31 | 2022-12-31 | 0001493152-23-010285 | EDGAR | — |
| 2022-03-29 | 2021-12-31 | 0001493152-22-008028 | EDGAR | — |
| 2021-03-31 | 2020-12-31 | 0001493152-21-007461 | EDGAR | — |
| 2020-03-30 | 2019-12-31 | 0001493152-20-005309 | EDGAR | — |
| 2019-04-01 | 2018-12-31 | 0001493152-19-004614 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-13 | 2025-09-30 | 0001708599-25-000133 | EDGAR | 26K words |
| 2025-08-11 | 2025-06-30 | 0001708599-25-000089 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0001708599-25-000053 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0001708599-24-000026 | EDGAR | — |
| 2024-08-09 | 2024-06-30 | 0001493152-24-030988 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0001493152-24-019248 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0001493152-23-041126 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0001493152-23-028478 | EDGAR | — |
| 2023-05-12 | 2023-03-31 | 0001493152-23-016642 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0001493152-22-031357 | EDGAR | — |
| 2022-08-12 | 2022-06-30 | 0001493152-22-022361 | EDGAR | — |
| 2022-05-13 | 2022-03-31 | 0001493152-22-013348 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-25 | 0001708599-26-000018 | EDGAR | 3K words |
| 2026-03-23 | 0001708599-26-000010 | EDGAR | — |
| 2026-01-28 | 0001708599-26-000005 | EDGAR | — |
| 2026-01-15 | 0001708599-26-000003 | EDGAR | — |
| 2025-12-10 | 0001708599-25-000138 | EDGAR | — |
| 2025-11-13 | 0001708599-25-000135 | EDGAR | — |
| 2025-11-12 | 0001708599-25-000130 | EDGAR | — |
| 2025-11-03 | 0001708599-25-000126 | EDGAR | — |
| 2025-10-06 | 0001708599-25-000122 | EDGAR | — |
| 2025-09-15 | 0001708599-25-000110 | EDGAR | — |
194 total filings indexed. 164 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001708599 |
| Ticker | SER |
| Exchange | NYSE |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | AL |
| Website | https://www.serinatherapeutics.com |
| Listed | 2024-03-27 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report